AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative
medicine company leading the development and commercialization of
first-in-class devices and autologous cellular therapies for skin
restoration, today announced that it has rejoined the broad-market
Russell 3000® Index following the conclusion of the 2023 Russell
indexes annual reconstitution, effective after the U.S. market
opens on June 26, 2023.
The annual Russell indexes reconstitution captures the 4,000
largest U.S. stocks as of April 28, 2023, ranking them by total
market capitalization, including both the Russell 3000 and Russell
Microcap® Indexes. Membership in the U.S. all-cap Russell 3000
Index, which remains in place for one year, means automatic
inclusion in the small-cap Russell 2000® Index as well as the
appropriate growth and value style indexes. FTSE Russell determines
membership for its Russell indexes primarily by objective,
market-capitalization rankings, and style attributes.
“We are pleased to rejoin the globally recognized Russell
indexes,” said Jim Corbett, Chief Executive Officer of AVITA
Medical. “We believe our inclusion will expand our exposure to the
investment community and broaden our investor base, further
advancing our strategic growth initiatives.”
Russell indexes are widely used by investment managers and
institutional investors for index funds and as benchmarks for
active investment strategies. Approximately $12.1 trillion in
assets are benchmarked against Russell’s U.S. indexes. Russell
indexes are part of FTSE Russell, a leading global index
provider.
For more information on the Russell 3000 Index and the Russell
indexes reconstitution, go to the “Russell Reconstitution” section
on the FTSE Russell website.
Authorized for release by the Chief Executive Officer of AVITA
Medical, Inc.
ABOUT AVITA MEDICAL, INC.AVITA Medical® is
a regenerative medicine company leading the development and
commercialization of devices and autologous cellular therapies for
skin restoration. The RECELL® System technology platform, approved
by the FDA for the treatment of thermal burn wounds and
full-thickness skin defects and for repigmentation of stable
depigmented vitiligo lesions, harnesses the regenerative
properties of a patient’s own skin to create Spray-On Skin™ cells.
Delivered at the point-of-care, RECELL enables improved clinical
outcomes. RECELL is the catalyst of a new treatment paradigm and
AVITA Medical is leveraging its proven and differentiated
capabilities to develop first-in-class cellular therapies for
multiple indications.
In international markets, AVITA Medical products are approved
under the RECELL System brand to promote skin healing in a wide
range of applications including burns, soft tissue repair,
vitiligo, and aesthetics. The RECELL System is TGA-registered in
Australia, received CE-mark approval in Europe and has PMDA
approval in Japan.
To learn more, visit www.avitamedical.com.
ABOUT FTSE RUSSELLFTSE Russell is a global
index leader that provides innovative benchmarking, analytics and
data solutions for investors worldwide. FTSE Russell calculates
thousands of indexes that measure and benchmark markets and asset
classes in more than 70 countries, covering 98% of the investable
market globally.
FTSE Russell index expertise and products are used extensively
by institutional and retail investors globally. Approximately $20.1
trillion is currently benchmarked to FTSE Russell indexes. For over
30 years, leading asset owners, asset managers, ETF providers and
investment banks have chosen FTSE Russell indexes to benchmark
their investment performance and create ETFs, structured products
and index-based derivatives.
A core set of universal principles guides FTSE Russell index
design and management: a transparent rules-based methodology is
informed by independent committees of leading market participants.
FTSE Russell is focused on applying the highest industry standards
in index design and governance and embraces the IOSCO Principles.
FTSE Russell is also focused on index innovation and customer
partnerships as it seeks to enhance the breadth, depth and reach of
its offering.
FTSE Russell is wholly owned by London Stock Exchange Group.
For more information, visit www.ftserussell.com.
FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. These
forward-looking statements generally can be identified by the use
of words such as “anticipate,” “expect,” “intend,” “could,” “may,”
“will,” “believe,” “estimate,” “look forward,” “forecast,” “goal,”
“target,” “project,” “continue,” “outlook,” “guidance,” “future,”
other words of similar meaning and the use of future dates.
Forward-looking statements in this press release include, but are
not limited to, statements concerning, among other things, our
ongoing clinical trials and product development activities,
regulatory approval of our products, the potential for future
growth in our business, and our ability to achieve our key
strategic, operational, and financial goal. Forward-looking
statements by their nature address matters that are, to different
degrees, uncertain. Each forward-looking statement contained in
this press release is subject to risks and uncertainties that could
cause actual results to differ materially from those expressed or
implied by such statements. Applicable risks and uncertainties
include, among others, the timing and realization of regulatory
approvals of our products; physician acceptance, endorsement, and
use of our products; failure to achieve the anticipated benefits
from approval of our products; the effect of regulatory actions;
product liability claims; risks associated with international
operations and expansion; and other business effects, including the
effects of industry, economic or political conditions outside of
the company’s control. Investors should not place considerable
reliance on the forward-looking statements contained in this press
release. Investors are encouraged to read our publicly available
filings for a discussion of these and other risks and
uncertainties. The forward-looking statements in this press release
speak only as of the date of this release, and we undertake no
obligation to update or revise any of these statements.
FOR FURTHER INFORMATION:
Investors & MediaAVITA Medical,
Inc.Jessica EkebergPhone +1-661-904-9269
investor@avitamedical.commedia@avitamedical.com |
Avita Medical (NASDAQ:RCEL)
Historical Stock Chart
From Apr 2024 to May 2024
Avita Medical (NASDAQ:RCEL)
Historical Stock Chart
From May 2023 to May 2024